BEIGF:OTCMKTS
BeOne Medicines
US$ 21,95
0,00%
(0,00) 1D
9 de jun., 12:49:46 GMT-4 · USD
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para BEIGF…
Valor de mercado
44,66 bi
Volume médio
0,00
Volume
0,00
Alto — 52 sem
US$ 24,92
Baixo — 52 sem
US$ 21,95
Beta
0,84
Ações em circulação
1,43 bi
Nº de funcionários
12 mil
Valor de mercado
44,66 bi
Volume médio
0,00
Volume
0,00
Alto — 52 sem
US$ 24,92
Baixo — 52 sem
US$ 21,95
Beta
0,84
Ações em circulação
1,43 bi
Nº de funcionários
12 mil
Notícias
De fontes da web e parceiros de notícias
MarketBeat
·
há 4 horas
BeOne Medicines (NASDAQ:ONC) Stock Rating Cut to Hold at Zacks Research
AD HOC NEWS
·
há 14 horas
BeOne Medicines stock gained 1.00 percent on October 5 as targets rose
Perfil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Sobre BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Funcionários12 mil
Data de fundação28 de out. de 2010
Sede-
Setor-